- Home
- PEGA vs BBIO Comparison
PEGA vs BBIO Comparison
Compare PEGA & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEGA
- BBIO
- Stock Information
- Founded
- PEGA 1983
- BBIO 2015
- Country
- PEGA United States
- BBIO United States
- Employees
- PEGA N/A
- BBIO N/A
- Industry
- PEGA EDP Services
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- PEGA Technology
- BBIO Health Care
- Exchange
- PEGA Nasdaq
- BBIO Nasdaq
- Market Cap
- PEGA 8.7B
- BBIO 7.6B
- IPO Year
- PEGA 1996
- BBIO 2019
- Fundamental
- Price
- PEGA $99.21
- BBIO $41.73
- Analyst Decision
- PEGA Buy
- BBIO Strong Buy
- Analyst Count
- PEGA 14
- BBIO 13
- Target Price
- PEGA $101.00
- BBIO $56.67
- AVG Volume (30 Days)
- PEGA 782.4K
- BBIO 2.5M
- Earning Date
- PEGA 07-23-2025
- BBIO 07-31-2025
- Dividend Yield
- PEGA 0.12%
- BBIO N/A
- EPS Growth
- PEGA 156.48
- BBIO N/A
- EPS
- PEGA 2.14
- BBIO N/A
- Revenue
- PEGA $1,642,666,000.00
- BBIO $127,415,000.00
- Revenue This Year
- PEGA $14.21
- BBIO $102.05
- Revenue Next Year
- PEGA $6.55
- BBIO $54.69
- P/E Ratio
- PEGA $46.12
- BBIO N/A
- Revenue Growth
- PEGA 14.29
- BBIO N/A
- 52 Week Low
- PEGA $56.49
- BBIO $21.62
- 52 Week High
- PEGA $113.67
- BBIO $41.90
- Technical
- Relative Strength Index (RSI)
- PEGA 54.05
- BBIO 69.82
- Support Level
- PEGA $97.91
- BBIO $39.65
- Resistance Level
- PEGA $102.08
- BBIO $41.36
- Average True Range (ATR)
- PEGA 2.12
- BBIO 1.51
- MACD
- PEGA -0.69
- BBIO 0.35
- Stochastic Oscillator
- PEGA 44.20
- BBIO 97.37
About PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.